Business Description
Sensei Biotherapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US81728A1088
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 10.59 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.19 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -23.7 | |||||
3-Year EPS without NRI Growth Rate | -20.6 | |||||
3-Year FCF Growth Rate | -21.6 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 52.6 | |||||
9-Day RSI | 48.78 | |||||
14-Day RSI | 49.79 | |||||
6-1 Month Momentum % | 77.75 | |||||
12-1 Month Momentum % | -27.27 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 11.92 | |||||
Quick Ratio | 11.92 | |||||
Cash Ratio | 11.65 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 5.4 | |||||
Shareholder Yield % | 6.17 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -41.25 | |||||
ROA % | -36.13 | |||||
ROIC % | -306.29 | |||||
ROC (Joel Greenblatt) % | -402.66 | |||||
ROCE % | -38.76 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.39 | |||||
Price-to-Tangible-Book | 0.39 | |||||
EV-to-EBIT | 1.02 | |||||
EV-to-EBITDA | 1.06 | |||||
EV-to-FCF | 1.07 | |||||
Price-to-Net-Current-Asset-Value | 0.44 | |||||
Price-to-Net-Cash | 0.45 | |||||
Earnings Yield (Greenblatt) % | 98.04 | |||||
FCF Yield % | -125.94 |